Implantable cardioverter defibrillators work -- so why aren't we using them?

Simpson, Christopher S.
July 2007
CMAJ: Canadian Medical Association Journal;7/3/2007, Vol. 177 Issue 1, p49
Academic Journal
The author comments on the article of D. Birnie and colleagues about the use of implantable cardioverter defibrillators as an effective means to reduce the death rate among survivors of cardiac arrest, which is published within the issue. He remarks that the study demonstrated the marked difference between Canada and the U.S. with respect to the use of the therapy. He argues that there are considerable administrative and economic barriers in Canada to the adoption of new technologies.


Related Articles

  • Sudden cardiac death: opportunities for prevention. Morgan, J. M.; Cowan, J. C.; Camm, A. J.; McComb, J. M. // Heart;Jun2006, Vol. 92 Issue 6, p721 

    The evidence base for implantable cardioverter-defibrillator (ICD) therapy requires expansion of guidance/indications to allow UK physicians to treat a broader range of patients. The ICD clinical consultees to the National Institute for Health and Clinical Excellence (NICE) review current...

  • Cameron Health Completes Enrollment in Pivotal FDA Clinical Study of the SICD( r) System.  // Biomedical Market Newsletter;5/9/2011, p507 

    The article reports that Cameron Health Inc. has completed enrollment in its pivotal FDA (U.S. Food & Drug Administration) clinical study of completely subcutaneous implantable defibrillator S-ICD System. Under the study, 330 patients were enrolled who were at risk for sudden cardiac arrest...

  • The long-term survival and the risks and benefits of implantable cardioverter defibrillators in patients with hypertrophic cardiomyopathy. O'Mahony, Constantinos; Lambiase, Pier D.; Quarta, Giovanni; Cardona, Montserrat; Calcagnino, Margherita; Tsovolas, Konstantinos; Al-Shaikh, Shereen; Rahman, Shafiqur M.; Arnous, Samer; Jones, Sue; McKenna, William; Elliott, Perry // Heart;Jan2012, Vol. 98 Issue 2, p116 

    Objective Implantable cardioverter defibrillators (ICDs) are routinely used to prevent sudden cardiac death (SCD) in selected hypertrophic cardiomyopathy (HCM) patients, but the determinants of device-related complications, therapies and long-term cardiovascular mortality in ICD recipients are...

  • Women might not benefit from implantable defibrillators.  // Journal of Business (10756124);10/1/2009, Vol. 24 Issue 20, pA20 

    The article focuses on a study published in the journal "Archives of Internal Medicine" in which implantable cardioverter-defibrillators do not show significant reduction in the risk of cardiac death among women with advanced heart failure. However, the implantable devices in men showed...

  • Implantable Defibrillators Reduce Death By 23% in Landmark Heart Failure Trial: NIH Study Indicates Need to More Aggressively Identify and Protect Patients at Risk for SCA.  // Journal of Cardiovascular Management;May/Jun2004, Vol. 15 Issue 3, p28 

    Reports on the results of the clinical trial for the implantable cardioverter-defibrillator therapy in people with heart failure in the U.S. Efficacy of the treatment in preventing sudden cardiac death; Safety profile in terms of general adverse events; Reason behind the underutilization of the...

  • Maximum potential benefit of implantable defibrillators in preventing sudden death after hospital admission because of heart failure. Setoguchi, Soko; Nohria, Anju; Rassen, Jeremy A.; Stevenson, Lynne Warner; Schneeweiss, Sebastian // CMAJ: Canadian Medical Association Journal;3/17/2009, Vol. 180 Issue 6, p611 

    Background: Implantable defibrillators are recommended for the prevention of sudden cardiac death in patients with heart failure. However, criteria to identify those who would benefit most from this therapy are lacking. We assessed the maximum potential benefit of preventing sudden death in...

  • Boston Scientific gets CE mark for Confient ICD to treat SCD.  // Medical Device Daily;10/12/2007, Vol. 11 Issue 196, p1 

    The article reports that Boston Scientific's Confient implantable cardioverter-defibrillator (ICD), a cardiac rhythm management device to treat sudden cardiac death (SCD), has received the CE-mark approval. The device has an AV Search Hysteresis feature designed to reduce unnecessary right...

  • Monitoring an unstable heart.  // Mayo Clinic Health Letter;Jun2006, Vol. 24 Issue 6, p1 

    Offers information on the use of an implantable cardioverter-defibrillator (ICD) to help prevent death from sudden cardiac arrest by quickly calming a chaotic heart. Description of two heart rhythm disorders; Individuals in which an ICD serves to be the most effective therapy to prevent sudden...

  • Cardiac implantable electronic devices in end-stage renal disease patients: preservation of central venous circulation. Lopera, Gustavo; Beathard, Gerald; Exaire, Jose; Carrillo, Roger // Journal of Interventional Cardiac Electrophysiology;Jun2012, Vol. 34 Issue 1, p101 

    The article offers recommendations for the use of implantable cardioverter-defibrillator (ICD) therapy for primary and secondary prevention of sudden cardiac death (SCD) in end-stage renal disease (ESRD) patients. It suggests offering epicardial or subcutaneous cardiac implantable electronic...

  • Single-chamber ICD, single-zone therapy in primary and secondary prevention patients: the simpler the better? González-Enríquez, S.; Rodríguez-Entem, F.; Expósito, V.; Castrillo-Bustamante, C.; Canteli, A.; Solloso, A.; Madrazo, I.; Olalla, J. // Journal of Interventional Cardiac Electrophysiology;Dec2012, Vol. 35 Issue 3, p343 

    Background: It is now well established that implantable cardioverter defibrillator (ICD) implantation reduces mortality in patients at increased risk of sudden cardiac death. However, the best programming parameters remain controversial. Our traditional policy has followed a simple approach in...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics